Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Expert Opin Drug Discov. 2015 Feb 8;10(4):427–439. doi: 10.1517/17460441.2015.1006194

Figure 1.

Figure 1

A. Chemical structure of sorafenib. B. Cellular targets of sorafenib. Sorafenib blocks auto-phosphorylation of multiple RTKs, including VEGFR1/2, PDGFR, FLT3 and RET. It is also a direct inhibitor of RAF-1, wild-type BRAF and the mutant V600E BRAF. RTK, receptor tyrosine kinase; RET, ret proto-oncogene; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase; PTEN, phosphatase and tensin homolog, PI3K, phosphoinositide 3-kinase; mTOR, mechanistic target of rapamycin.